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Abstract

Background
Governments and other payers are yet to determine optimal processes by which to review the safety,
effectiveness, and cost-effectiveness of technologies and procedures that are in active use within health
systems, and rescind funding (partially or fully) from those that display poor profiles against these parameters.
To further progress a disinvestment agenda, a model is required to support payers in implementing
disinvestment in a transparent manner that may withstand challenge from vested interests and concerned
citizens. Combining approaches from health technology assessment and deliberative democratic theory, this
project seeks to determine if and how wide stakeholder engagement can contribute to improved decisionmaking processes, wherein the views of both vested and non-vested stakeholders are seen to contribute to
informing policy implementation within a disinvestment context.

Methods/design
Systematic reviews pertaining to illustrative case studies were developed and formed the evidence base for
discussion. Review findings were presented at a series of deliberative, evidence-informed stakeholder
engagements, including partisan (clinicians and consumers) and non-partisan (representative community
members) stakeholders. Participants were actively facilitated towards identifying shared and dissenting
perspectives regarding public funding policy for each of the case studies and developing their own funding
models in response to the evidence presented. Policy advisors will subsequently be invited to evaluate
disinvestment options based on the scientific and colloquial evidence presented to them, and to explore the
value of this information to their decision-making processes with reference to disinvestment.

Discussion
Analysis of the varied outputs of the deliberative engagements will contribute to the methodological
development around how to best integrate scientific and colloquial evidence for consideration by policy
advisors. It may contribute to the legitimization of broad and transparent stakeholder engagement in this
context. It is anticipated that decision making will benefit from the knowledge delivered through informed
deliberation with engaged stakeholders, and this will be explored through interviews with key decision
makers.
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Background: Governments and other payers are yet to determine optimal processes by which to review the safety,
effectiveness, and cost-effectiveness of technologies and procedures that are in active use within health systems,
and rescind funding (partially or fully) from those that display poor profiles against these parameters. To further
progress a disinvestment agenda, a model is required to support payers in implementing disinvestment in a
transparent manner that may withstand challenge from vested interests and concerned citizens. Combining
approaches from health technology assessment and deliberative democratic theory, this project seeks to determine
if and how wide stakeholder engagement can contribute to improved decision-making processes, wherein the
views of both vested and non-vested stakeholders are seen to contribute to informing policy implementation
within a disinvestment context.
Methods/design: Systematic reviews pertaining to illustrative case studies were developed and formed the
evidence base for discussion. Review findings were presented at a series of deliberative, evidence-informed
stakeholder engagements, including partisan (clinicians and consumers) and non-partisan (representative
community members) stakeholders. Participants were actively facilitated towards identifying shared and dissenting
perspectives regarding public funding policy for each of the case studies and developing their own funding
models in response to the evidence presented. Policy advisors will subsequently be invited to evaluate
disinvestment options based on the scientific and colloquial evidence presented to them, and to explore the value
of this information to their decision-making processes with reference to disinvestment.
Discussion: Analysis of the varied outputs of the deliberative engagements will contribute to the methodological
development around how to best integrate scientific and colloquial evidence for consideration by policy advisors. It
may contribute to the legitimization of broad and transparent stakeholder engagement in this context. It is
anticipated that decision making will benefit from the knowledge delivered through informed deliberation with
engaged stakeholders, and this will be explored through interviews with key decision makers.
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Background
Disinvestment as a policy approach to healthcare safety
and quality

As health system managers increasingly seek ways in
which to improve quality of care and constrain resource
use, the concept of health technology reassessment with
potential for disinvestment has gained currency. Having
existed for some time in the realms of business and
manufacturing, the consideration of disinvestment practices within healthcare is relatively new, with antecedents in evidence-based medicine (EBM) and health
technology assessment (HTA). Disinvestment seeks to
improve health outcomes by evaluating existing health
services, identifying those that do not provide safe, effective, or cost-effective care, and redirecting funding
away from these services and towards those with superior safety, effectiveness, and cost-effectiveness profiles
through a variety of policy approaches [1,2]. It does not
by definition need to be a dichotomous choice to fund
or not to fund; disinvestment can occur by degrees,
whereby subsidies may be restricted to subgroups of
patients for whom there is evidence of potential for
benefit based on specific clinical characteristics (referred
to as ‘refining the indications’ for service provision).
While there has been international interest in disinvestment, it remains an essentially theoretical construction that has only been operationalized in a limited
manner in few jurisdictions [3]. A number of challenges
are faced in developing and implementing the concepts
of disinvestment into pragmatic policy approaches.
While methods for the assessment of new and emerging
technologies and services have become relatively wellestablished in the processes of HTA, governments and
other payers are still to determine the optimal processes
by which to review existing technologies and procedures.
Often these pre-date the EBM and HTA era and thus
have escaped rigorous evaluation of safety, effectiveness,
and cost-effectiveness, yet are entrenched as offerings
within healthcare.
In considering processes for refining funding for established technologies and services, contested elements may
include: what is counted as ‘evidence’ and by whom; the
‘burden’ of evidence required; and the consultative components that may be necessary to support disinvestment decisions. A best-practice model to support payers in pursuing
explicit efforts towards disinvestment in a manner that
may withstand challenge from vested interests and interested citizens is yet to emerge [1].
With a view to bridging this divide between policy and
practice, a competitively funded, Australian-based research project was established in 2009. The purpose of
the ASTUTE Health study (Assessing Service and Technology Use To Enhance Health) is to develop, trial, and
evaluate a transparent process by which to refine the
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indications for services, to ensure investment in procedures with favourable safety, effectiveness, and costeffectiveness profiles. Independent of government, this
multidisciplinary project seeks to incorporate methods
from HTA and deliberative democratic theory and, as
such, represents a novel approach to the development of
evidence-based health policy wherein the views of both
vested and non-vested stakeholders are seen to contribute valuably and uniquely to informing policy decisions
within a disinvestment context.
Deliberative democracy: Involving the community

Deliberative democratic methods have gained prominence
in recent years, driven in part by the rise of evidenceinformed policy-making and the potential for these methods to assist in involving the broader community in democratic governance that extends beyond voting [4,5].
Current methods of policy development and decision making are considered to contain democratic deficits, created
by the opaque, but often dominant roles of strong special
interest groups/experts, an inability to represent heterogeneous public interests, and a lack of processes by which to
encourage input from adequately informed members of
the general public [6,7]. Additionally, there remains a need
for ‘health services to be accountable to users as taxpayers,
voters, and consumers’ [8].
Debate around ‘the fair and reasonable allocation of
resources has become a prominent one in modern day
discourses about healthcare’ [9]. Health funding decisions, particularly those which relate to some level of reimbursement retraction (more effective redistribution
notwithstanding) may carry significant moral implications, be highly contested (by a range of stakeholders)
and historically have not been made in an explicit and
transparent manner. The complexity and contestability
inherent in disinvestment decisions position such health
policies as key candidates for the integration of deliberative methods in their construction [4].
Within this study, members of the community will be
involved in making explicit the barriers and facilitators
of disinvestment (with reference to both the specific case
studies and the broader disinvestment context), and to
determine whether stakeholder engagement could contribute to creating improved and transparent decisionmaking processes in this policy domain. Additionally, it
is anticipated that the colloquial evidence collected from
community members will enhance the scientific evidence base derived from the systematic reviews, and balance the perspectives of other more actively vested
stakeholders and special interest groups.
Experiential knowledge: involving vested stakeholders

In order to align this research project with the realities
of policy making, to which a wide variety of stakeholders
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contribute, the perspectives, knowledge, and interests of
vested stakeholders (clinical and consumer groups) will
also be included in addition to the views of non-partisan
citizens. This broad, evidence-informed engagement
seeks to mimic and enhance the diverse range of inputs
with which health policy decision-makers must grapple
in the course of negotiating health policy development;
such inputs have not always been transparent. Greater
accountability in decision making will be supported by
the structured frame of discussion offered by a process
of facilitated deliberation around an evidence base.
Health resource allocation decisions also may need to
go beyond a narrow scientific view of evidence and consider ‘colloquial’ evidence [4] alongside scientific evidence. Deliberative and other consultative processes may
usefully be employed to combine these different kinds of
evidence to increase the likelihood of achieving ‘sound
and acceptable decisions’ (Stern et al. in [4]). By including clinical and consumer groups in these processes, it is
anticipated that critical experiential knowledge will be
added to the scientific evidence collected through systematic review.
Herein, we describe the implementation of methods
for broad stakeholder deliberative engagements, a frame
for evaluation, and a costing of the process.

Methods/design
Overview of the study design

Two case studies were selected for the project: assisted
reproductive technologies (in vitro fertilization (IVF) and
intracytoplasmic sperm injection (ICSI) with specific
reference to the safety, effectiveness, and costeffectiveness related to female age, male age, and cycle
rank); and vitamin B12 and folate pathology tests. The
services/procedures associated with both of these case
studies are publicly subsidised under Australia’s universal
health insurance scheme, Medicare.
The first phase of the project (see Figures 1 and 2)
entailed systematic reviews for each case study. These
reviews demonstrated the variable effectiveness profiles
associated with both assisted reproductive technologies
(ART) and B12/folate tests [10,11], and collated a wide
range of evidence for stakeholders to consider, including
ethical and costing analyses.
In the second phase, the findings of these reviews will
be presented at a series of deliberative, evidenceinformed stakeholder engagements designed to include
both motivated stakeholders who have traditionally
dominated health policy development (clinicians and
consumers) and also the voice of the ‘average citizen’
which is often not heard or excluded from policy
decision-making [7]. Each of the stakeholder groups will
be actively facilitated towards identifying both shared
and dissenting perspectives regarding public funding
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policy for each of the case studies in response to the evidence presented.
Finally, in phase three, policy advisors will be presented with the results of the reviews, alongside the perspectives of all the stakeholder groups collected in phase
two. They will be invited to formulate a disinvestment
opinion based on both the scientific and colloquial evidence presented to them, and then to explore their
decision-making processes and rationale with reference
to the disinvestment context.
The remainder of this paper will focus on project phases
two and three as these represent the novel components of
the process. A description of the systematic reviews and
their findings has been published elsewhere [10,11].
Selection of case studies

The two case studies of ART and pathology testing for vitamin B12 and folate were considered to elucidate an understanding of the broader issues surrounding the
development of disinvestment policy [12]. Both were identified as candidates for further assessment under disinvestment initiatives because they met multiple criteria on a
proposed identification framework [1], including substantial temporal and geographic variation in usage and early
evidence of differential effectiveness across patient subgroups. Additionally, the case studies were considered to
engender a variety of different demands on a disinvestment
process and were selected in part for their illumination of
different potential responses from stakeholders. The ART
case study was considered more likely to draw strongly on
values-based arguments in the face of relatively low but rising volumes and high cost, while the vitamin B12/folate
testing case study represented an ostensibly non-controversial, low-cost service, albeit one with high and rising
utilization.
To this end, the case studies were selected: to meet the
dual goals of research and policy development; to create an
innovative approach to shared decision-making; to evaluate
the feasibility of participatory processes involving a wide
range of stakeholders; and to learn about how these groups
perceive disinvestment processes in the context of
evidence-informed deliberation.
Designing evidence-informed deliberative stakeholder
engagement

The deliberative engagements for each case study were
designed and piloted by a multidisciplinary team (including clinical advisors). Ethics approval for all arms of this
study was obtained from The University of Adelaide’s
Human Research Ethics Committee.
The case studies were undertaken in a staggered progression to allow for refinement of the process with experience: ART was examined first, followed by the B12/
folate case study.
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Phase 1:
Evidence reports

Health policy

Systematic review

Ethical analysis

Economics

Policy making process,
history, international
comparisons

Safety & effectiveness with
reference to female age,
male age & cycle rank

Constructions of need;
capacity to benefit, equity

Differences in marginal cost
by age & cycle rank

Phase 2:
Stakeholder engagement
Round I: Canvassing range & diversity of opinion

Clinicians

Community

Consumers

Policy advisors (State & Federal)

Round II: Development of consensus/majority funding models
(incorporating outcomes of Round I & extra evidentiary requests)

Community

Clinicians

Consumers

Phase 3:
Policy deliberation & analysis
Process evaluation

Policy advisors (Federal)

Figure 1 Process of ART case study.

In order to avoid capture by vested interests, to maintain
a power balance, and to cater for differing levels of expertise, stakeholders were consulted in separate engagements.
Potentially partisan stakeholders were not mixed with lay
citizens, but the ideas generated by each group were communicated to the subsequent groups to share knowledge
and allow cumulative solutions to be constructed.
Recruitment

Methods of recruitment for the engagement sessions
varied between the groups and are detailed in Table 1,

with recruitment strategies constructed to take into account the objectives of each deliberative event alongside
considerations of feasibility.
Participants in the clinical, consumer, and policy
groups were purposively recruited on the basis of their
experiential knowledge, stature as opinion-leaders, and
role in decision-making processes. Nominations for clinical participants were sought from key stakeholder bodies in the respective fields of reproductive medicine and
pathology. Nominees were then approached with a letter
of invitation, as were key practitioners in each field.

Watt et al. Implementation Science 2012, 7:101
http://www.implementationscience.com/content/7/1/101

Page 5 of 12

Phase 1:
Evidence reports

Systematic review

Utilisation

Pathology audit

Guideline review

Diagnostic accuracy of
B12/folate tests

Examination of Medicare
data to determine basic
utilisation patterns

Examination of routinely
collected laboratory data to
determine B12/folate test
positivity rates

Identification &
examination of advice
provided by current clinical
practice guidelines

Phase 2:
Stakeholder engagement
General
Practitioners (1)

Pathology
providers:

General
Practitioners (2):

Exploration of
utilisation; evidentiary
requests

Exploration of
utilisation; evidence;
potential for change

Exploration of evidence;
potential for change

Specialists:

Community:

Exploration of
utilisation; evidence;
potential for change

Role of testing;
expectations; value of
test with uncertain
evidence base

Phase 3:
Policy deliberation & analysis
Process evaluation

Policy advisors (Federal)

Figure 2 Process for vitamin B12/folate pathology testing case study.

Consumers (ART case study only) responded to an advertisement placed in the highest-circulating daily newspaper in South Australia. Due to the ubiquity of the test,
an appropriate consumer group for the B12/folate case
study could not be identified.
Policy advisors across portfolios, divisions, and
branches (state and federal) directly related to health
funding were approached by the project’s Chief Investigators and invited to participate in the evaluative component of the project, with further policy participants
identified through snowballing.
Recruitment of community members sought participants descriptively representative of Australian population demographics, although it is acknowledged that
such a small sample cannot be completely statistically or
politically representative [13]. Pre-determined stratification criteria (gender, age, household income) were applied by an independent recruitment company to a
randomly sampled group of South Australian residents,
thus avoiding oversampling from older or more
economically-advantaged groups.
Sample sizes for the community engagements were
based on those advocated for citizen’s juries [14-17],

while the other engagements were slightly smaller,
reflecting the specificity of recruitment requirements.
These were particularly rigorous for the ART case
study, because the sensitivity of the topic under discussion required exclusion criteria designed to minimise
any potential harm to participants. We felt a duty of
care towards consumers who had not been able to
achieve a successful live birth because this can be the
source of much ongoing distress. The sample sizes
were considered optimal to deliver a diversity of opinions while still allowing full and active participation
in ‘communicative processes and will-formation’ [18].
From a research perspective, the sample sizes were
sufficient to test the logistical and practical components of the engagement design [6], while also evaluating the benefits and drawbacks of the use of
deliberative engagements in future decision making beyond the bounds of research.
Structure of the deliberative engagements

The two case studies differed in their structure for a
number of reasons. The ART case study engaged each
stakeholder group in two ‘rounds’; this was designed to
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Table 1 Details of recruitment processes and outcomes
Stakeholder Sample size
group

Method/s of recruitment

Selection and exclusion criteria

Demographics

Medically qualified clinicians working
in ART and associated fields such as
maternal/fetal medicine and
neonatology

4 males; 4 females
Role and practice†:
Reproductive medicine:
5/8

Participated: Round I N = 8

Exclusion criteria:

Participated Round II N = 6

- Participants and/or their partners who
had undertaken ART in the 3 years
immediately preceding the forum

Other (including
obstetrics/gynaecology
and neonatology): 3/8

Case study 1: assisted reproductive technologies
Clinicians

Recruited: N = 19

Nominations from key representative
bodies in the field of reproductive
medicine*; purposive sampling of
key opinion leaders; snowballing

- Participants currently undertaking ART
treatment or planning to undertake
ART in the foreseeable future
Consumers

Recruited: N = 32

Participated: Round I N = 9

Purposive recruitment seeking
participants with a broad range of ART
experiences - advertisement seeking
participants placed in The Advertiser
(Adelaide’s daily newspaper). Detailed
topic and exclusion criteria‡

- Females 18 years and older who had
undertaken ART treatment, regardless
of infertility aetiology
- Up to 3 males, partners of women
who had undertaken ART

Participated: Round II N = 7

Exclusion criteria:

Reason for exclusion:

- Participants and/or their partners who
had undertaken ART in the 3 years
immediately preceding the forum

Withdrew interest: 2

1 male; 8 females

Unable to contact
further: 4
Unable to attend:1

- Participants currently undertaking ART
treatment or planning to undertake
ART in the foreseeable future

Related to other
participant: 1

Community

ART undertaken <3
years prior: 12

- An inability to speak and read English

Currently undergoing
ART: 1

- Pregnant women

Recruited: N = 25

18 years or older; matched against
predetermined stratification criteria for
broadly proportional representation
of the Australian population§

7 males; 7 females

Exclusion criteria:

Age:

- Participants currently undergoing ART
or who had undergone ART

18-30: 4/14

Participated: Round II N = 10

- Participants planning to undertake
ART in the foreseeable future

31-40: 1/14

Reasons for exclusion:

- An inability to speak and read English

41-50: 3/14

Participated: Round I N = 14

Random sample of SA population,
identified and contacted by
independent recruitment company

6 participants had previously
participated in a separate citizens’ jury

Withdrew interest: 5

51+: 6/14

Missed recruitment
deadline: 5

- Pregnant women

Post-tax income:
<AU$800/week: 7/14

Did not meet inclusion
criteria: 1

>AU$800/week: 7/14

Case study 2: B12 and folate pathology tests
Clinicians:
General
Practitioners

Recruited: N = 26
Participated: N = 14
Reasons for exclusion:
Withdrew interest: 4
Quota filled: 8

Letters of invitation sent to all GPs
Registered GP working part-time or
from 4 South Australian Divisions of
full-time in active practice in
General Practice (Adelaide Hills;
South Australia
Adelaide Western; Adelaide Northern’
Yorke Peninsula); respondents selected
on ‘first-come’ basis with 2 places
reserved for GPs from regional areas

9 males; 5 females
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Table 1 Details of recruitment processes and outcomes (Continued)
Clinicians:
Specialists

Recruited: N = 7

Purposive sampling with key
practitioners sent letter of invitation;
snowballing.

Participated: N = 6
Reasons for exclusion:
Withdrew interest: 1
Pathology
providers

Recruited: N = 9
Participated: N = 9

Participants must be registered specialist
practitioners (including, but not limited
to: geriatricians, physicians,
endocrinologists and haematologists)
working full-time or part-time in active
practice in South Australia

4 males; 2 females
Speciality:
General physician: 3/6
Endocrinologist:1/6
Haematologist: 2/6

Nominations from national public and
private pathology interest groupsǁ;
purposive sampling of key opinion
leaders; snowballing

Participants must be working full-time
or part-time in administrative,
management or laboratory roles in
private or public pathology providers
in Australia

5 males; 3 females
Role and practice:
Public pathology: 2/8
Private pathology: 5/8
Management: 1/8

Community

Recruited: N = 16

Random sample of SA population,
identified and contacted by
independent recruitment company

Participated: N = 11
Reasons for exclusion:
Withdrew interest: 5

18 years or older; matched against
predetermined stratification criteria
for broadly proportional representation
of the Australian population§

5 males; 6 females
Age:
18-30: 3/11
31-40: 2/11
41-50: 3/11
51+: 3/11
Post-tax income:
<AU$800/week: 5/11
>AU$800/week: 6/11

NOTES: ART assisted reproductive technologies; GP general practitioner; SA South Australia.
*including the Australian Medical Association; Royal Australian and New Zealand College of Obstetricians and Gynaecologists; Royal Australian College of
Physicians; Royal Australian College of General Practitioners; Fertility Society of Australia.
†
Many of the reproductive medicine specialists held dual qualifications/clinical roles in gynaecology.
‡
Copy available from the authors on request.
§
Stratification criteria based on national Australian Bureau of Statistics data and included: gender (50:50 male:female ratio); age (equal representation from 4 age
groups: 18–30; 31–40; 41–50; 51+); and household disposable income (post-tax) (50:50 household income <:>$800.00 per week).
ǁ including National Coalition of Public Pathology, Australian Association of Pathology Practices; Australasian Association of Clinical Biochemists; Healthscope;
Sonic; and Primary Health.

allow adequate time to address the morally and emotionally complex nature of the topic. It also allowed the
opportunity for each group to hear the perspectives of
the other stakeholders, and question, incorporate, or discard those views as they deliberated further.
Consumer engagements for the ART case study were
approximately four hours long, and held on a mid-week
evening over dinner. They included short evidence presentations and a wide-ranging participant deliberation.
Sessions were designed to build from participants’
experiences, allowing them to extrapolate to consider
broader implications for the healthcare system.
The process for the B12/folate case study was streamlined, with general practitioners (equivalent to primary
care physicians) the only group consulted twice. With
the largest proportion of pathology test requests in Australia arising from primary care [19], it was considered
critical to place significant emphasis on interaction with
general practitioners in order to ascertain their views on
the tests, the evidence, and the potential for change
through the lens of primary care. The practicalities of assembling national-level stakeholders across multiple

rounds for the purposes of the research precluded a second round of engagement.
The deliberative engagements for clinicians (specialists,
general practitioners, and pathology providers) were
designed to incorporate their significant experiential knowledge. Four-hour sessions, drawing on existing knowledge
and experience of participants, included short evidence
presentations and a meal, allowing approximately three
hours of participant deliberation. The majority of these sessions were held in the state of South Australia, with only
the pathology provider engagement taking place in another
state (New South Wales; due to the participants being
nominated by their national-level organisation).
The community engagements were held over two days
(non-consecutive for ART; consecutive for the B12/folate
case study), designed to allow time for information sharing, deliberation, and relationship building, acknowledging that the participants were not content experts.
Table 2 details the structure for each of the sessions, all
of which included a variety of information presentation
(adapted for the informational needs of each group),
group activities, and deliberation. In all groups,
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Table 2 Daily agendas for the community engagements: assisted reproductive technologies and pathology testing for
vitamin B12 and folate
Assisted reproductive technologies:
Day 1
Objectives:

Specific Activities:

Share knowledge regarding health policy in Australia, assisted reproductive
technologies and frameworks for decision-making.

Welcome, introductions and orientation (large group)

Explore preliminary responses and construct funding criteria.

Presentations and questions: health policy in Australia, ART safety
and effectiveness (large group); costs; ethical frameworks (100 minutes;
large group)
Activity and discussion: International comparisons to identify perceived
strengths and weaknesses of different funding models (40 minutes;
large group)
Activity and deliberation: Construct exhaustive list of possible criteria
that could be used to restrict funding for ART (large group); refine this
list (small groups) and vote on top 5 criteria that should and should not
be considered for imposing funding restrictions (individuals) (total 90
minutes)
Discussion: other information required to construct funding
scenarios (30 minutes; large group)

Day 2
Objectives:

Specific Activities:

To determine if the criteria for the public funding of ART should be
changed; why; and how

Presentation and questions: information requested after day 1
(15 minutes; large group)
Presentation and questions: summary of findings from other
stakeholders (15 minutes; large group)
Activity: Construction of funding scenario (45mins; individual/pairs)
Activity and deliberation: Consensus building on funding scenarios (75
minutes; large group)
Debrief and close

Pathology testing for vitamin B12 and folate:
Day 1
Objectives:

Specific Activities:

To determine what considerations should be taken into account when
making decisions about how B12/folate pathology tests are publicly
subsidised

Discussion: experience and expectations as healthcare
consumers (50 minutes; large group)
Presentation and questions: pathology in General Practice;
defining the policy context (75 minutes; large group)
Discussion: Responding to utilization changes (45 mins; large group)
Activity and participant questions: General testing epidemiology (60
minutes; large group)

Day 2
Objectives:

Specific Activities:

To determine what considerations should be taken into account when
making decisions about how B12/folate pathology tests are publicly subsidised

Presentation/questions: B12/folate testing (30 minutes; large group)
Presentation and questions: Rise in level of B12/folate testing and
stakeholder responses (15 minutes; large group)
Activity and deliberation: What things should be considered when making
decisions about how much we should publicly subsidise B12/folate
pathology tests? List of factors for consideration (large group); determine
5 most important factors (small group); consensus building activities
(large group) (total 150 minutes)
Debrief and close
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deliberation occurred in a variety of formats, including
large and small group brainstorming, small group discussion, and open discussion. Experts who had presented information (including a general practitioner,
pathologist (B12/folate case study), ethicist (ART case
study), and research staff ) were available for questioning
on points requiring clarification or to further inform,
but did not take part in deliberations.
In line with the evaluative nature of these engagements, phase three sessions with the policy makers will
be structured around a presentation of the evidence base
and discussion of the responses from stakeholders, followed by a set of open-ended questions that will allow
them to explore the outcomes, strengths, weaknesses,
and overall value of the process from a policy perspective. The two-hour roundtable sessions will be held in
the Australian Capital Territory and South Australia,
and commence with an overview of the project’s outcomes. Participants will be encouraged to engage in an
open dialogue regarding each of the specific case studies
and a reflection on the nature of disinvestment policy
more broadly constructed.

Evidentiary and other inputs

For both of the case studies, the majority of information
presented to the participants was based on systematic
reviews of the relevant literature that were specifically
commissioned as a component of this research [10,11].
These were supplemented with information modules pertaining to other relevant aspects of health funding decision-making, including: description of the technology/
procedure; an overview of health funding policy in
Australia (complete with Medicare cost and utilisation data
by location and demographics) and elsewhere; economic
considerations [20]; and broad ethical frameworks to support decision-making [21] (see Figures 1 and 2).
Prior to the roundtable discussions, clinical participants
were provided with a brief summary of the topic and a
broad indication of the context for the discussion. At each
session, expert members of the research group presented
the information modules described above and remained
available for questioning for the duration of the evening.
Participants in the consumer engagement (ART case
study) were told the topic and context for discussion
prior to the engagements, but were not provided with
any detailed information. Evidentiary inputs were limited
in the first round of engagement, which focussed on
international variation in ART funding and previously
proposed changes to ART funding in Australia. The second round of engagement included a brief presentation
on age-specific safety and effectiveness, alongside the
perspectives of other stakeholder groups and the funding
models that they had constructed.
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Based on multiple reports of lay citizens engaging successfully in technically complex areas of health policy
[22-24], this process of community engagement was
designed around evidence-informed deliberations, requiring participants to be technically informed on a
topic without influencing their deliberation [5]. For the
community groups in each case study, the information
presented was designed to be accessible to participants
with no prior knowledge of the topic areas.
Aware that the topic of ART can engender highly emotional reactions, written versions of the information
modules designed to be accessible to a lay audience were
distributed one week prior to the engagement session to
allow participants the chance to consider their views on
the public funding of ART before entering into a potentially evocative group deliberation. This was not considered necessary for the B12/folate case study due to its
relatively more benign characteristics.
During these sessions there were a number of presentations from expert witnesses with regard to: current
Australian health funding policies; safety and effectiveness parameters of the technologies; and economic [20]
and ethical considerations [21] (see Table 2). Details of
the clinical application of ART were also presented, and
the B12/folate case study included educative components
related to the interpretation of test characteristics (e.g.,
diagnostic accuracy as measured by sensitivity and specificity) and clinical aspects of test ordering. The speakers
who presented each of these sessions remained available
to answer questions during subsequent deliberations.
Policy advisors will be provided with a detailed briefing
paper one week prior to the session, providing an overview
of the systematic review and summary points from each
stakeholder engagement. Brief presentations will be provided by senior research staff, who will remain available to
answer questions and provide clarification on any points
for the remainder of the engagement session.

Facilitation

Clinical, community (citizen), and consumer (patient)
engagement sessions were facilitated by an independent and neutral facilitator, who was not involved in
participant deliberation or questioning of experts (except on points of clarity) and did not provide expert
information. The facilitator managed the group interactions, ensuring that all participants had the opportunity to be heard; encouraged in-depth discussion and
negotiation amongst the participants; and assisted participants in identifying areas of consensus and persistent disagreement in order to progress the discussion
constructively.
Sessions with policy advisors will be facilitated by the
project’s Chief Investigators, who will play a dual role in
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facilitating the evaluative discussion and providing information regarding the process and its outcomes.
Facilitators drew on micro- and meso-level research
questions to inform the specific topics of case studies. At
the beginning of each session and throughout the discussion, participants were asked to consider specific questions,
with participants in the ART case study being asked, for example: ‘Should the criteria for public funding of IVF be
changed? If yes, how and why? If no, why?’; and those participating in the B12/folate case study: ‘What things should
be considered when making decisions about how much we
should publicly subsidise B12/folate pathology tests?’
Meta-questions regarding the barriers and facilitators to
disinvestment more generally and the role of various stakeholders in health policy decision-making were also
explored with each group. Supplementary questions varied
according to the participant’s role (clinician, consumer, citizen (community), policy advisor) and time was allowed for
open, participant-driven discussion.
Members of the community, consumer, and clinical
engagement groups were offered a small honorarium for
each session they attended in order to cover any
expenses associated with their participation. Policy advisors will not be offered an honorarium for their participation, because it is considered that consultations of this
nature align with current government activity and thus
fall within the remit of their professional roles.
Data collection and analysis

Given the dual research/policy development objectives
of this project, collection and dissemination of both the
deliberative and analytical outputs of the stakeholder
engagements were considered critical [22]. That is, our
analysis is set to generate both a thematic representation
of the content of deliberations, as well as more metalevel discussion around the ideological and material
implications of the arguments and values articulated.
After obtaining consent from participants, deliberations were audio-recorded and transcribed verbatim by
an experienced Hansard reporter (all speech machine
typed in full as opposed to shorthand in real time). This
occurred contemporaneously for all engagements.
The research component of the project demands that
the content of participants’ deliberations be analysed
in order to examine the social processes of negotiation
and practical reasoning inherent in disinvestment decision-making. As such, the transcripts will be analysed
using a synthetic approach to discourse analysis [25],
combining the traditions of conversation analysis/
ethnomethodology with an interest in broader cultural
and historical power relations [26]. This approach
allows a focus on the structure of participants’
accounts (how they were put together rhetorically so
as to appear credible or persuasive in the deliberative
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context) as well as their function in justifying broader
disinvestment outcomes.
Deliberative outputs of the process will be reviewed
and discussed by the research staff with reference to
the transcripts, in addition to the notes, lists, and
other written outputs produced by the participants. Because pre-formulated options (requiring only a consensus ‘yes/no’ decision) were not offered to the
participants, a singular, consensual ‘outcome’ of the deliberation may not be immediately (or ever) evident.
For example, in preliminary analyses we see that participants revised their positions over the course of the
discussions. This appears particularly evident in
engagements with community groups, and requires
that the report detailing the deliberative output of this
group be endorsed by the participants after the conclusion of deliberation.
Costs

Table 3 details the expenses associated with the engagement components of each case study (completed at the
Table 3 Summary of expenses associated with
stakeholder engagements (all costs are in Australian
Dollard, incurred over 2009 to 2012)
Expense category

ART case study

B12/folate
case study

Total

Honoraria

$7,849

$11,231

$19,080

Participant recruitment

$3,653

$3,500

$7,153

$7,293

$9,887

$17,180

Venue
> Food and drinks (inc.
room hire)
> Equipment hire
Expert witnesses
Facilitation
> Facilitation associated
costs
Stenography

-

$427

$427

$7,040

$9,152

$16,192

$6,978

$3,600

$10,578

$5,608

$2,622

$8,229

$7,514

$6,913

$14,427

Flights
> Participant
> Research

-

$1,663

$1,663

$2,474

$2,752

$5,226

-

$160

$160

Accommodation
> Participant
> Research
Project management
Staff salaries (administrative
support*)
Other operating costs
Total

$350

$803

$1,153

$4,800

$4,800

9,600

$35,000

$35,000

$70,000

$1,945

$531

$2,476

$90,504

$93,041

$183,544

* Does not include research staffing costs for the development of systematic
review evidence, costings and ethical analyses, or supervision time by Chief
Investigators.

Watt et al. Implementation Science 2012, 7:101
http://www.implementationscience.com/content/7/1/101

time of writing). These costs may be variable, and will
depend on the purpose, context, and extent of engagement. Although these costs may appear large at first
sight, they are small compared to the cost implications
of continued use (or otherwise) of the relevant technologies. The costs associated with undertaking the systematic reviews on which the stakeholder engagements are
based are not included in this summary, nor is the time
of lead study investigators.

Discussion
Drawing on the strengths of health technology assessment and deliberative democratic theory, this program
of research attempts to create replicable processes for
both governments and private payers to develop transparent, evidence-based policy decisions in the domain of
disinvestment.
Systematic review is well-accepted in Australian health
policy decision-making, particularly as a component of
health technology assessment. We are interested if systematic review will be seen as equally crucial to precede
disinvestment decisions, possibly by reducing information asymmetry between policy advisors and clinical and
other stakeholder groups.
We hypothesise that the deliberative engagement with
the community will be seen to add valuable information to
a policy decision, helping to balance the vested interests of
single-issue consumer groups. However, it may be that the
outcomes of engagement with partisan stakeholders (clinicians and consumers) are viewed with more caution; an assessment of the value of engaging with these groups will be
an important outcome of this process.
At the time of writing, the program has been successful in engaging a wide range of stakeholders in constructive and wide-ranging deliberations. Analysis of the
varied outputs of the deliberative engagements will contribute to the methodological development around how
to best integrate scientific and colloquial evidence for
consideration by policy advisors and may contribute to
the legitimization of broad and transparent stakeholder
engagement in this context.
Embedding disinvestment research more firmly within
the established domain of quality and safety may reorientate these discussions towards provision of the
most effective care, facilitate more transparent discussions, and help alleviate the incorrect perception that
disinvestment is a process of rationing.
From a process perspective, there are clear challenges
in recruiting appropriate stakeholder groups, informing
deliberations in a neutral manner and supporting active
deliberation. Stakeholder groups will vary across technologies and procedures examined, and it is unlikely that
a ‘one size fits all’ approach to the undertaking of a
process such as this will be appropriate. There remains a
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role for policy makers to further define the parameters of
stakeholder engagement that they will accept as making a
legitimate contribution to policy development, and this
study hopes to progress this. In doing this though, it is critical that this type of process not be used as a form of ‘market research,’ or to retrospectively justify policy decisions.
This work is situated at the intersection of health policy, health technology assessment, and deliberative democracy. As such, it is theoretically possible to evaluate it
from a number of perspectives; the outcomes can be
variously defined and evaluated. While the ultimate outcome of this work may appear to be a disinvestment decision for each of the case studies (removal or restriction
of funding), this overlooks the fact that a change of such
magnitude is reliant on multiple actors and processes
outside the bounds of the research sphere; the researcher is not the implementer of policy change. As
such, failure to implement an actual disinvestment decision from policy groups should not be considered a failure of this process. However, as this project is designed
to contribute pragmatically to policy development (in
both the public and private funding domains), it is considered that those actively involved in the development
of health funding policy in Australia are in a unique position to evaluate the project’s outputs.
As such, senior policy advisors within state and federal
levels of government across multiple relevant portfolios will
be approached for their views on the usefulness of the
process, its further development, and how the individual
components, alongside the deliberative and analytical outputs, might contribute to disinvestment policy development.
We will attempt to uncover from policy advisors what
they consider to be the evidentiary requirements for disinvestment processes. They will also be asked to consider—from resource and priority points of view—the
desirability and practicality of applying this process
across the large number of publicly funded procedures
in Australia and the necessary and sufficient conditions
that would be required for full or partial disinvestment
to be enacted. Views on the processes’ limitations will
also be explicitly sought from policy advisors.
While participatory processes hold great promise for
their potential to offer a diversity of knowledge and experience to the policy-making process, they do not represent any guarantee of creating a smoother, less
contentious policy process. However, when coverage
decisions contain significant moral dimensions and
dilemmatic elements, decision making may indeed benefit from the experiential knowledge delivered through
informed deliberation with engaged stakeholders.
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